Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Making markets in Europe

Given the complexities of marketing to multiple countries in Europe, not to mention the price controls, it might seem logical that companies thinking about doing mergers would look for deals that would give them an entry into the U.S. market. But Strakan Group Ltd. and ProSkelia SA are taking the opposite tack, arguing that by combining they will be more attractive to U.S. companies seeking a partner to sell their products

Read the full 717 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE